You’re invited to join Dicerna’s 2020 Virtual R&D Day
Dicerna management will be joined by therapeutic experts for a discussion of key disease areas and development programs, including:
Phase 1 proof-of-concept data for RG6346, an investigational GalXC™ RNAi treatment candidate for chronic hepatitis B virus (HBV) infection in development with Roche
Multidose data from the PHYOX™3 trial of nedosiran, an investigational GalXC RNAi treatment candidate for primary hyperoxaluria (PH)
First preclinical data on Dicerna’s RNAi technology in extrahepatic tissues
When
Thursday, August 6, 2020
Program: 10:00 a.m. – 12:00 p.m. ET
Where
Webcast Information
Visit the Investors & Media section of the Dicerna website at
investors.dicerna.com
Dial-in: (800) 708-4539 or +1 (847) 619-6396
ID: 49860522
A replay of the webcast will be archived on Dicerna’s website following the conclusion of the live event
For more information, please contact Lauren Stival, Senior Director of Investor Relations at Dicerna at lstival@dicerna.com or 617-514-0461
